Update: Phase I clinical trial to assess safety, tolerability and feasibility of pNGVL4aCRTE6E7L2 HPV DNA vaccine administration via intramuscular TriGrid™ electroporation delivery system in patients with HPV16-positive high-grade cervical, vulvar or vaginal intraepithelial neoplasia

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-09-01 DOI:10.1016/j.ygyno.2025.04.018

Kimberly Levinson , Rebecca Arend , Tullia Rushton , Peter Ketch , Benjamin Matthews , Dana Lewis , Teresa Boitano , Christopher Mayer , Hao Wang , Sejong Bae , Darin Ostrander , Ashish Solanki , Alexis Peay , Misty West , Emily O'Brien , Fibiana Oladipo , Abbie Kleckley , Chien-Fu Hung , Charles Leath , T.C. Wu , Richard Roden

引用次数: 0

查看原文本刊更多论文

更新：I期临床试验评估pNGVL4aCRTE6E7L2 HPV DNA疫苗在hpv16阳性高级别宫颈、外阴或阴道上皮内瘤变性患者中通过TriGrid™肌内电穿孔给药系统的安全性、耐受性和可行性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy